At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Duke University Medical Center
- Class Naphthalenes; Propionic acids
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes; Coronary artery restenosis; Disseminated intravascular coagulation; Thrombosis
Most Recent Events
- 15 May 2008 Discontinued - Phase-II for Disseminated intravascular coagulation in Japan (PO)
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 15 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the pharmacokinetics section